Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Xiangnan Guan(Oregon Health & Science University), Namrata S. Patil(Gene Therapy Laboratory), Sanjeev Mariathasan, John Silva, Barzin Y. Nabet(Gene Therapy Laboratory), Shyam Srivats, Katherine Nutsch, Pallavi Daggumati, Lisa McGinnis, Alexis Dunkle(Duke University Hospital), Robert L. Hendricks, David S. Shames(The University of Texas Southwestern Medical Center), Melissa L. Johnson(Sarah Cannon Research Institute), Nandini Molden, Delvys Rodríguez‐Abreu(Hospital Universitario Insular de Gran Canaria), Wendy Connolly, Antoîne Italiano(Université de Bordeaux), Byoung Chul Cho(Yonsei University), Ignacio Gil‐Bazo(Navarre Institute of Health Research), Ira Mellman(Genesys (United States)), Patrick Chang, Robert J. Johnston(Gene Therapy Laboratory), Stephanie Mittman, Ellen Duong, Chia-Jung Han, Enriqueta Felip(Universitat Autònoma de Barcelona), Ruozhen Hu, Raymond D. Meng, Eugene Y. Chiang, Yoonha Choi, Karl L. Banta
Cited by 121
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k